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ABSTRACT  
 
Introduction: The spinal cord stimulation (SCS) has been described as a valuable 
neuromodulating procedure in the management of chronic and medically untreated 
neuropathic pain. Although, many studies have discussed the use of this technique, a 
question still remains regarding its efficacy in different medical conditions with 
different etiology in the long term. The aim of this paper is to discuss the risks, 
complications, cost-effectiveness and results of SCS in patients affected by chronic 
neuropathic pain based on the comprehensive literature review. 
Methods: Bibliographic search of references from 1950 to 2016 using the databases 
MEDLINE, LILACS, SciELO, PubMed, and applied language as selection criteria, 
choosing preferably recent articles written in Portuguese, Spanish or English. 
Results: Based on literature review, SCS is a safe, reversible, adjustable and 
nondestructive surgical procedure demonstrating a significant effect in the reduction 
of pain intensity and improvement in quality of life in these patients. Furthermore, in 
spite of the initial high cost to its application, SCS has been associated with lower 
rates of complications and high rates of cost-effectiveness when compared to standard 
therapies. 
 
Conclusion: Although used in medical conditions with different etiology, the 
procedure is still an effective and a cost-effective approach to neuropathic pain, 
mainly in patients affected by failed back pain syndrome (FBSS) and complex 
regional pain syndrome (CRPS). 
 
Keywords: Spinal cord stimulation, neuropathic pain, pain management, 
neurosurgical procedure, electric stimulation therapy 
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INTRODUCTION 
 
Pain is defined as an unpleasant sensation and emotional experience related to actual or 
potential tissue damage. It may be divided into nociceptive, caused by activation of 
pain receptors related to tissue damage, or neuropathic pain, caused by a primary lesion 
or dysfunction in the central, peripheral or both nervous systems (1-5).  
Recent studies have reported a significant increase in the number of patients affected by 
refractory neuropathic pain. The actual prevalence of neuropathic pain in general 
population has been estimated from 6.9% to 8%. About 74% of neuropathic pain cases 
present with moderate to severe intensity. Neuropathic pain comprises more than 17% 
of patients' pain complaint (3,4,6-12). 
Management of neuropathic pain is a challenge often associated with high rates of 
disappointment. Usually, neuropathic pain is managed by multidisciplinary team and 
includes pharmacological treatment by opioids, anticonvulsants, tricyclic 
antidepressants, and corticosteroids. In a few scenarios, non-steroidal anti-
inflammatory drugs are used. Furthermore, occupational therapies can be conducted 
(1,4,9,10).  
The surgical management of neuropathic pain includes ablative and non-ablative 
neurosurgical approaches. These include rhizotomy, sympathectomy, cordotomy, 
hypophysectomy, regional infusion of sympatholytic infiltrations, and intrathecal 
administration of drugs. Recently, electrical stimulation therapies, such as spinal cord 
stimulation (SCS), motor cortex stimulation (MCS) and deep brain stimulation (DBS) 
have been described (13-23). 
 
SCS, also known as dorsal column stimulation (DCS) (24,25), is a reversible, 
adjustable and nondestructive surgical approach. Painful symptoms are controlled 
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through the spinal electrical stimulation, using epidural electrode placed in the posterior 
horn of the spinal cord (13,15,16,22,26-28). 
SCS was firstly described by Shealy et al. (29), in 1967, as an alternative for ablative 
neurosurgical procedures in the management of refractory pain. Since then, it has been 
estimated that more than 12,000 SCS systems are sold annually worldwide. SCS has 
shown significant results in the treatment of a wide range of pain disorders (27). 
Our aim is to clarify the indications, risks, complications and prognosis of patients 
treated with SCS for neuropathic pain. We will discuss the efficacy of SCS in the 
control of pain and cost-effectiveness of procedure. 
METHODS 
We searched MEDLINE, LILACS, SciELO, and PubMed databases using "neuropathic 
pain" and "spinal cord stimulation" keywords. We included articles published between 
1950 and 2016, written in Portuguese, Spanish or English language, and involving only 
human subjects. Only the relevant studies were selected for this review (Figure 1). 
PHYSIOLOGICAL MECHANISMS OF SCS 
SCS mechanism is complex and involves more than just one model or mechanism. SCS 
is associated with sequentials or simultaneous interactions of multiple physiological 
mechanisms of pain conduction (30-36). The classical mechanism of pain was 
described in 1965 by Melzack and Wall (36). Recently, the effect of SCS on blood flow 
and somatosensory system had been described (Figure 2) (16,30-33). 
In 2000, Kemler et al. (32) described the possible relationship between SCS and 
changes in microcirculation blood flow in patients (n=36) affected by unilateral 
complex regional pain syndrome (CRPS). The study showed that 66.7% (n=24) of 
patients were responsive in the stimulation test with the SCS system. The total of 
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91.7% of these patients (n=22/24), whose pain was located in hand (58%) and in foot 
(33.4%), had undergone the previous unsuccessful sympathectomy. The authors 
concluded that patients with lower vasoconstriction rates had a significant pain 
improvement (p<0.01) when compared to control patients. This has indicated a 
decrease in sympathetic tone and an increase in vasodilation during the use of the SCS 
system. Nevertheless, SCS did not result in any microcirculatory changes as there was 
no difference when compared to baseline values of patients or the contralateral, 
clinically unaffected side. 
In 2016, Deogaonkar et al. (31), presented the results of the functional magnetic 
resonance imaging (fMRI) in patients (n=10) affected by CRPS in lower limbs, who 
had previously undergone SCS. The results of this study showed significant differences 
(p<0.05) in resting-state connectivity between SCS off and optimal state in several 
regions related to pain perception. The regions included the left frontal insula, right 
primary and secondary somatosensory cortices, as well as in regions involved in the 
default mode network (DMN), such as the precuneus. In addition, these changes in the 
connectivity across the entire brain during the optimal SCS were found to result in pain 
relief. Furthermore, the results indicated the increased connection strength between the 
somatosensory and DMN, and the decreased connection strength between 
somatosensory and limbic areas. The authors suggested that pain relief from SCS may 
be reducing a negative emotional processing associated with pain, allowing 
somatosensory areas to become more integrated into the default mode activity. 
In 2012, Moens et al. (37) showed similar results to those discussed by Deogaonkar et 
al. (31), in patients (n=20) affected by failed back surgery syndrome (FBSS). The 
authors investigated the deactivation of the bilateral medial thalamus and its 
connections to the rostral and caudal cingulate cortex and the insula. The study also 
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showed immediate pain relief obtained by short-term SCS correlated negatively with 
activity in the inferior olivary nucleus, the cerebellum, and the rostral anterior cingulate 
cortex. 
SELECTION OF PATIENTS 
 
The adequate selection of the patients directly affects the success of the SCS approach. 
During the selection, different factors have been considered, such as the etiology of 
pain, type and localization of pain, age of the patient, and the radiological and 
neurological findings summarized in Table 1 (20-22,28,30-31,37-44).  
Patients considered for SCS procedure are required to comply with the following 
criteria: 
- Patients with medical intractability of neuropathic pain (20-22,26,32,38,45-49); 
- Patients that reported the reduction of 50% or more in pain intensity in the trial 
simulation (3-15 days) by percutaneous implantation when compared with the 
baseline (20-22,26,32,38,45-49); 
- Patients diagnosed with complex regional pain syndrome (CRPS), type I - A 
level of evidence (20-22,27,28,30,38-43); 
- Absence of the major psychiatric disorder, including somatization disorder 
complaints (20-22,38); 
- Patients with unsuccessful control of neuropathic pain after the repeated 
functional or ablative surgical procedure for pain treatment (20-22,38,45); 
- Patients with pain not associated with malignancy (38). 
During the surgical procedure of trial implantation, patients should be asked to indicate 
the location of parenthesis (change of sensibility correlated to the spinal segment 
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stimulated), since it is relevant to confirm that the resultant parenthesis overlaps with 
the painful area in order to achieve good analgesia (20-22,26,28,45).  
 
RESULTS IN PAIN MANAGEMENT 
 
It is essential to determine the cause of pain in order to effectively manage it. In terms 
of the neuropathic pain etiology, SCS has been applied in the treatment of 
deafferentation  pain, central pain, phantom limb pain, causalgia, myelopathy, 
oncologic pain, lumbosacral fibrosis, postherpetic neuralgia, FBSS, CRPS, reflex 
sympathetic dystrophy, spinal cord, brainstem or brain injury, and others (3,13-
15,22,32,33,38,42,43,46-49,50-57). Since there are many different types of neuropathic 
pain, there is no reason to believe that one procedure will be effective in the treatment 
of all conditions. 
In 2006, Lee et al. (38) reported that SCS is an effective treatment for pain associated 
with FBSS, refractory angina pectoris, peripheral vascular disease, and CRPS type I. 
Between 60% - 80% of patients with FBSS, peripheral vascular disease and CRPS type 
I had a significant improvement in the quality of life related to returning to daily 
activities. The SCS procedure in patients affected by refractory angina pectoris resulted 
in a significant decrease in hospital admissions and chest pain, as well as an increased 
exercise duration. In addition, the comparison between SCS and open surgical 
procedures showed that SCS demonstrated less morbidity rates and similar or higher 
rates of pain control and improvement in the quality of life. 
In 2008, Olsson et al. (50) presented the results of SCS in children (n=7; 100% girls) 
diagnosed with CRPS type I, within the mean age 13+1.1 years (ranging from 11 to 14 
years). The pain was localized in foot (57.1%; n=4), hand (14.3%; n=1), knee (14.3%, 
n=1), and knees (14.3%; n=1). Complications were reported in 14.3% (n=1) of patients 
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affected by subcutaneous infection, which resulted in the surgical removal of the SCS 
system. All the patients were treated with sympathetic blocks (SB), without a 
therapeutic effect. However, the SCS procedure had a pain relieving effect after 1 or 2 
weeks of trial stimulation. The pain alleviation was complete in 71% (n=5) of the 
patients, ranging from 1 to 8 years after the intervention, after another 2–6 weeks. 
In their paper in 2008, Kemler et al. (47) described the SCS results in patients 
diagnosed with CRPS type I (n=36), whose follow-up lasted 5 years. The authors 
demonstrated an effective long-term pain treatment for 63% (n=24) of the implanted 
patients. The total of 100% (n=36) and 53% (n=19) of these patients presented more 
than 50% of pain reduction and more than 80% of pain intensity by the visual analog 
scale (VAS) in the first postoperative year, respectively. The percentage of patients 
who reported at least 30% reduction in pain with SCS was reduced from 100% to 41% 
in the fifth postoperative year. During the five-year treatment, 29 technical 
complications were reported, including lead migration, pulse generator replacement, 
explanation, and reimplantation of the system. About 72% (n=21) of the complications 
took place in the first 2 years, while the annual complication rate in the remaining 3 
years was 5%. Guerts at al. (48), Williams et al. (55), Harke et al. (56), Kumar et al. 
(58), Kemler et al. (46,47,49), Van-Ejis et al. (54), reported similar results on pain 
management. 
In 2012, Van-Ejis et al. (54) described the results of the comparison between the 
standard therapy and the use of SCS in patients (n=61) affected by CRPS. The standard 
therapy included physical therapy, topical dimethyl sulfoxide, analgesics, 
transcutaneous stimulation, and sympathetic blockade. In these patients, 90.1% (n=55) 
were treated with the standard therapy and 9.9% (n=6) were included for the SCS 
treatment. The overall mean pain relief after one year was 35% and the mental 
  - 9 - 
component improved in both groups, while none of the SCS treated patients showed a 
clear improvement in the functional outcome. No significant difference of effect on the 
physical component was demonstrated as well. 
In their 2016 study, Kim et al. (14) presented the results of the continuous thoracic 
sympathetic ganglion block associated with SCS in patients (n=3) diagnosed with 
unilateral CRPS in their upper limbs. The mean age of patients was 53.6 years, ranging 
from 49 to 56 years. The authors concluded that the thoracic sympathetic block was 
efficient in the treatment of neuropathic pain of upper extremities once the approach 
was associated with improvement higher than 50% of basal pain. Nevertheless, this 
procedure often had temporary effects. Although, the authors indicated that SCS did 
not achieve the total control of pain, this approach avoided several complications taking 
place in the continuous sympathetic block.  
In 2011, Sears et al. (42) described the results of SCS in patients (n=35) diagnosed with 
CRPS (n=18) and FBSS (n=17). A total of 18 male and 17 female patients participated 
in the CRPS and FBSS groups, respectively. The mean age was 44.3 years and 51.6 
years, the duration of pain at the time of the surgery was 9.6 years and 8.5 years, and 
the duration of a follow-up after the surgery was 5.0 years and 3.8 years in CRPS and 
FBSS groups, respectively. More than 50% of the patients with CRPS reported more 
than 50% pain relief at a mean follow-up of 4.4 years, while 30% of the FBSS patients 
reported a 50% or greater improvement at a mean follow-up of 3.8 years. The review 
reported more than 50% pain relief in 55.6% of CRPS patients (p<0.01) and 30% of 
FBSS patients (p<0.01). Furthermore, 77.8% of CRPS patients (p=0.15) and 70.6% of 
FBSS patients (p=0.01) indicated that they would undergo a SCS surgery again for the 
same outcome. In this respect, Cruccu et al. (13), Kumar et al. (41), Taylor et al. (40), 
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Cameron (27), North et al. (59) and Kumar et al. (60) reported similar results on pain 
management obtained by conducting SCS in patients affected by FBSS. 
Simpson et al. (52), in 2009, and Wills et al. (61), in 2015, provided the results of the 
systematic review on the clinical effects of SCS in patients affected by neuropathic and 
ischemic pain. Their studies were based on more than 600 quotes identified from 13 
databases in the period from 1950 to 2014. The authors showed in this study that the 
presence of clinical benefits for refractory angina is showed in a short-term treatment. 
Furthermore, this also applies to the improvement of quality of life, enhancement of 
physical performance, reduction in the use of nitroglycerine, decrease in hospitalization 
admissions, and reduction in pain intensity and frequency in these patients. With this 
regard, in 1999, Vaarwerk et al. (62) presented the results of the SCS use in patients 
(n=517) diagnosed with refractory angina pectoris. The study included 71% male 
patients (n=367), a median follow-up was 23 months (ranging from 0 to 128), within 
the mean age 63.9+10.1 years. Therefore, this study and other authors, such as Murphy 
et al. (24), demonstrated the improvement, ranging from 3.5 to 2.1 (p<0.01), based on 
the New York Heart Association Functional Classification. In addition to the 
improvement, the total percentage of hospital admissions was reduced to 30 % 
(p<0.001).   
Numerous literary sources report variable success rates in the neuropathic pain 
management with SCS in patients affected by the section of the spinal cord conus and 
cauda equina, complete transverse section of the spinal cord, injury in multiple 
radicular roots, and phantom limb pain, as shown in Figure 3 (5,13,21,22,63,64). 
Patients diagnosed with CRPS, FBSS (Figure 4 and 5) and postherpetic neuralgia have 
shown significant success rates in pain management and cost-effectiveness associated 
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with low rates of complications. The total pain management was rarely obtained by the 




Although long-term complications rates of SCS can vary in this type of surgical 
procedure, such as: the presence of electrode migration (Figure 6), battery or pulse 
generator failures, hardware malfunction, also, the paresthesia in other body parts and 
superficial infections were associated to SCS approach. Furthermore, the low rates of 
electrode breakage, change of amplitude of pulse by bodily movements, unwanted 
stimulation, unsatisfactory positioning of the electrode or generator, urinary disturbs, 
cerebrospinal fluid leakage, subcutaneous hematomas, epidural hematomas, deep 
infections, aseptic meningitis, paralysis, spinal cord injury, headache, asthenia, 
dizziness, muscle spasms, and pain located at the incision, electrode, or receiver site are 
risks to be considered during and after the surgical act (13,27,32,38-40,46-49,68). 
In 2004, Cameron (27) summarized the 20-year application of SCS, including the data 
obtained from 51 research papers, comprising 2972 patients in total. This study 
specified complications related to technical or biological plots. The most common 
technical complications are battery or pulse generator failures, and electrode breakage 
and dislocation (27). The most frequently reported biological complications are 
cerebrospinal fluid (CSF) leakage, infections and pain located at the incision, electrode, 
and receiver site (27). It is important to underline that this study identified paralysis and 
electrode migration as the most serious and the most common SCS complication, 
respectively. In addition, this assessment showed that the majority of complications 
were not considered as life-threatening and could be mainly solved by removing the 
device.  
  - 12 - 
In 2005, Franzini et al. (69) presented the results of a retrospective analysis of a 22-year 
experience in 410 patients who underwent the SCS implantation. The authors reported 
displaced electrode, fractured electrode, other hardware malfunctions, subcutaneous 
hematomas, infection, CSF leakage, rotation of the pulse generator and discomfort at 
the pulse generator site in 21.5% (n=89), 5.9% (n=25), 8.1% (n=34), 4.4% (n=18), 
3.4% (n=14), 0.5% (n=2), 0.7% (n=3) and 1.2% (n=5) patients, respectively. 
In their study in 1989, Meglio et al. (66) presented the results of the use of SCS in a 
case series (n=100) of patients. The examined patients were affected by obstructive 
peripheral vasculopathy (n=40), previous herpes zoster infection (n=10), incomplete 
traumatic spinal cord lesion (n=15), root and/or nerve damage (n=9), cancer (n=11), 
earlier back surgery (n=19), and undetermined pain etiology (n=5). This study reported 
complications related to aseptic meningitis, infection, paralysis (paraplegia), rejection 
of the electrode leads, CSF leakage, and the system failure in 4% (n=4), 4% (n=4), 1% 
(n=1), 2% (n=2), 3% (n=3) and 4% (n=4), respectively. In this respect, all the cases of 
meningitis were treated with no permanent damage. Side effects, such as headache, 
asthenia, and dizziness were identified in 2% (n=2) of the patients. About 3% (n=3) of 
patients presented muscle twitching due to the radicular stimulation, and 1% (n=1) 
reported signs of muscular contraction caused by the activation of the pyramidal tracts. 
In terms of pain improvement, no clinical benefits of SCS in cancer pain or in central 
deafferentation pain were identified. Significant results were reported for vasculopathic 
pain and postherpetic neuralgia. Similar results were also found by Meglio et al. (67) 
and Cinio et al (65). 
The authors reported high rates of patients with the absence of complications (more 
than 50% of patients) and the presence of lead migration (17% of patients) as the main 
complication of SCS procedure. The technical complications affected more than 30% 
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of patients and represented the most common complication of this procedure. Paralysis 
indicated the lower incidence rate (less than 0.1%) and the most severe complication of 
this procedure. Furthermore, SCS has reported low rates of system rejection (less than 
2% of cases). 
Benefits of the neuropathic pain treatment by the SCS system include short 
hospitalization time, high rates of pain reduction following the procedure related to the 
reduction of pharmacological treatment costs, low rates of long-term complications, 
and the resources optimization. These factors, in addition to an increase in the life 
expectancy of the inhabitants of emerging countries, indicate the need for more clinical 




In 2006, Taylor et al. (39) presented the results of the systematic review and the meta-
analysis of the clinical SCS cost-effectiveness in the management of CRPS patients. 
This study comprised 25 case series, 1 randomized controlled trial and 1 cost-
effectiveness study. During the median follow-up period of 33 months, patients 
affected by CRPS type I or type II presented a significant pain relief higher than 50% in 
intensity in 67% of patients implanted with SCS system. The economic analysis based 
on the randomized controlled trial indicated a lifetime cost-saving of approximately 
€58,470 (US $60,800) by using SCS plus physical therapy compared to physical 
therapy. The mean cost per quality-adjusted life-year (QUALY) at a follow-up period 
of 12 months amounted to €22,580 (US $23,480). SCS has been proven a cost-effective 
and an efficient treatment of CRPS type I (A level evidence), while type II presented D 
level evidence with regards to cost-effectiveness.  
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In 2002, Kemler et al. (46) described the results of a cost-effectiveness analysis on the 
use of SCS in patients affected by chronic reflex sympathetic dystrophy (RSD) (n=54) 
in the first year of the postoperative follow-up. This study demonstrated that the SCS 
costs were mainly related to the implantation costs (€202,986), while the remaining 
costs were generated by test stimulation (€30,128) and complications (€11,904). 
Therefore, the authors concluded that the mean cost per patient for SCS procedure 
achieving significant results was €193,580. SCS associated with physical therapy and 
medical pain management was estimated to €171,153 and €229,624, respectively. 
In their study in 2008, Kemler et al. (47) presented the results of a cost-effectiveness 
analysis on the use of SCS in patients affected by chronic RSD (n=54) in the fifth year 
of the postoperative follow-up. It has also been concluded that SCS would be less 
expensive than alternative therapies after 3 years of the successful treatment, and in 2 
years it would be cost-effective for another period of 2-3 years. The study reported 99% 
(n=52) of the patients who affirmed to repeat the treatment, if necessary, for the same 
outcome. Similar results were found by Turner et al. (53), Hollingworth et al. (70), 
Dario et al. (71), and Ohnmeiss et al. (72) in their studies on pain management of 
FBSS, and Simpson et al. (52) in their research papers on patients affected by ischemic 
pain. 
Recent studies show that SCS has been associated with significant cost-effectiveness 
rates when compared to the conventional pharmacological pain management (Table 4). 
Regardless of the initial high cost of SCS, this treatment resulted in significant rates of 
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CONCLUSION  
 
SCS is an initial and a controversial procedure in which the substantial assessment 
demonstrated heterogeneous patients and methodologies, implying the high degree of 
difficulty related to the analysis of results. In this light, Kemler et al. (47) presented that 
only 56% (n=20/54) of patients with an implanted system were reported at the final 5-
year follow-up, despite the high patient satisfaction. 
Based on the literature review and authors' experience, recent studies have shown that 
SCS is an effective adjunctive therapy in patients with medically refractory neuropathic 
pain. Although, the total control of pain with SCS has not been commonly described, 
this procedure has been associated with significant improvement in life quality of these 
patients. 
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Figures 
 
Figure 1. Articles were searched in several databases, using the keywords 
“neuropathic pain" and "spinal cord stimulation". After applying the relevance, 
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Figure 2. Physiological mechanisms of SCS include more than just one model or 
mechanism, illustrating the association between the classical mechanism of pain 
described by Melzack and Wall (36) and the effect of SCS on blood flow and the 
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Figure 3. A patient affected by chronic phantom-limb pain was implanted with a 
cervical medullary electrode. The intraoperative radiography shows the positioning of 
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Figure 4. A patient diagnosed with chronic FBSS after lumbar arthrodesis underwent 
SCS implantation. The intraoperative radiography, in the sagittal plane, shows the 
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Figure 5. A patient affected by chronic FBSS after lumbar arthrodesis underwent 
SCS system implantation. The intraoperative radiography, in the sagittal plane, shows 
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Figure 6. A patient diagnosed with chronic FBSS after lumbar arthrodesis underwent 
SCS implantation. The intraoperative radiography, at the coronal section, shows the 
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Tables 
Table 1. Key points of the patient selection criteria 
 
Medically intractable pain 
Failure of other surgical procedures 
of pain control 
Pain reduction higher than 
50% in trial stimulation 
Absence of malignant neoplasms, 
psychiatric disorders or other 
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Table 2. Pain control rates of SCS  
Authors Year n Etiology Complete Pain 
Relief with SCS 
Mean Pain relief higher 
than 50% of baseline 
Mean 
follow-up 
Olsson et al. (50) 2008 7 CRPS 71% of patients 100% of patients 8 years 
Kemler et al. (47) 2008 36 CRPS 63% of patients 83% of patients 5 years 
Van-Ejis et al. (54) 2012 61 CRPS 0% of patients 0% of patients 1 year 
Kim et al. (14) 2016 3 CRPS 0% of patients 100% of patients 1 year 
Sears et al. (42) 2011 35 FBSS (n=17) 
CRPS (n=18) 
0% of patients 
0% of patients 
> 50% of patients 
> 50% of patients 
4 years 
5 years 
Harke et al. (56) 2002 28 PHN 0% of patients 82% of patients 3 years 
Kumar et al. (60) 2002 104 FBSS 0% of patients 88% of patients 5 years 
Williams et al. (55) 2009 1 CRPS 100% of patients 100% of patients 1 year 
Geurts et al. (48) 2012 84 CRPS 0% of patients 64% of patients 11 years 
Viswanathan et al., 
(41) 
2010 4 PLP 25% of patients 100% of patients 1 year 
*n = Number of patients; PHN = Postherpetic Neuralgia; CRPS = Complex Regional Pain 
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Table 3. Long-term complications rates of SCS 
Complication Incidence rates n (510 patients)* 
Absence of complications 59% 301 
Lead migration 17.4% 89 
Hardware malfunction 7.5% 38 
Lead breakage 4.9% 25 
Hematomas 3.5% 18 
Infection 2.8% 14 
Discomfort at the pulse generator 1% 5 
Cerebral Fluid Leak 1% 5 
Aseptic meningitis 0.8% 4 
Muscle spasms 0.6% 3 
Rotation of the pulse generator 0.6% 3 
Rejection of the system 0.4% 2 
Headache, asthenia, dizziness 0.4% 2 
Paralysis 0.1% 1 
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Table 4. Cost-effectiveness of main neuropathic pain therapies 
 
Authors n of 
patients 
Etiology Treatment Mean treatment cost 
Kemler et al. 
(46) 
18 CRPS SCS + PT EUR 171,153.00 
(in 1 year of follow-up) 
Kemler et al. 
(46) 
36 CRPS PT EUR 229,624.00 
(in 1 year of follow-up) 
Kemler et al. 
(46) 
24 CRPS SCS EUR 193,580.00 
(in 1 year of follow-up) 
Manca et al. 
(57) 
50 FBSS SCS + CPT EUR 12,653  
(in 0.5 year of follow-
up) 
Manca et al. 
(57) 
50 FBSS CPT EUR 2,594  
(in 0.5 year of follow-
up) 
Manca et al. 
(57) 
50 FBSS SCS + CPT £1,692 
(in 1 year of follow-up) 
Manca et al. 
(57) 
50 FBSS CPT £2,664 
(in 1 year of follow-up) 
Kumar et al. 
(41) 
52 FBSS CPT USD 38,029.00 
(in 5 years of follow-
up) 
Kumar et al. 
(41) 
52 FBSS SCS USD 29,123.00 
(in 5 years of follow-
up) 
*SCS = spinal cord stimulation; CPT = conventional pharmacological treatment; PT = 
physical therapy; CRPS = complex regional pain syndrome; FBS = failed back 
surgery syndrome. 
